• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

青蒿琥酯、氯喹和亚甲蓝对配子体的阻断作用。

Transmission-blocking activities of artesunate, chloroquine, and methylene blue on gametocytes.

机构信息

Shoklo Malaria Research Unit, Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Ramat, Tak, Thailand.

Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, England, United Kingdom.

出版信息

Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0085324. doi: 10.1128/aac.00853-24. Epub 2024 Jul 26.

DOI:10.1128/aac.00853-24
PMID:39058023
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11382624/
Abstract

is now the main cause of malaria outside Africa. The gametocytocidal effects of antimalarial drugs are important to reduce malaria transmissibility, particularly in low-transmission settings, but they are not well characterized for . The transmission-blocking effects of chloroquine, artesunate, and methylene blue on gametocytes were assessed. Blood specimens were collected from patients presenting with vivax malaria, incubated with or without the tested drugs, and then fed to mosquitos from a laboratory-adapted colony of (a major malaria vector in Southeast Asia). The effects on oocyst and sporozoite development were analyzed under a multi-level Bayesian model accounting for assay variability and the heterogeneity of mosquito infection. Artesunate and methylene blue, but not chloroquine, exhibited potent transmission-blocking effects. Gametocyte exposures to artesunate and methylene blue reduced the mean oocyst count 469-fold (95% CI: 345 to 650) and 1,438-fold (95% CI: 970 to 2,064), respectively. The corresponding estimates for the sporozoite stage were a 148-fold reduction (95% CI: 61 to 470) and a 536-fold reduction (95% CI: 246 to 1,311) in the mean counts, respectively. In contrast, high chloroquine exposures reduced the mean oocyst count only 1.40-fold (95% CI: 1.20 to 1.64) and the mean sporozoite count 1.34-fold (95% CI: 1.12 to 1.66). This suggests that patients with vivax malaria often remain infectious to anopheline mosquitos after treatment with chloroquine. Use of artemisinin combination therapies or immediate initiation of primaquine radical cure should reduce the transmissibility of infections.

摘要

现在是非洲以外地区疟疾的主要病因。抗疟药物的配子体杀伤作用对于降低疟疾的传染性很重要,特别是在低传播地区,但目前对 的配子体杀伤作用还没有很好的描述。评估了氯喹、青蒿琥酯和亚甲蓝对 配子体的阻断作用。从患有 vivax 疟疾的患者中采集血液标本,在有或没有测试药物的情况下孵育,然后用来自实验室适应的 (东南亚主要疟疾媒介)蚊群进行喂食。在一个多水平贝叶斯模型中分析了对卵囊和孢子发育的影响,该模型考虑了测定变异性和蚊子感染的异质性。青蒿琥酯和亚甲蓝,但不是氯喹,表现出强大的阻断作用。配子体暴露于青蒿琥酯和亚甲蓝分别使平均卵囊数减少 469 倍(95%CI:345 至 650)和 1,438 倍(95%CI:970 至 2,064)。对于孢子阶段,平均计数分别减少 148 倍(95%CI:61 至 470)和 536 倍(95%CI:246 至 1,311)。相比之下,高氯喹暴露仅使平均卵囊数减少 1.40 倍(95%CI:1.20 至 1.64),平均孢子数减少 1.34 倍(95%CI:1.12 至 1.66)。这表明患有 vivax 疟疾的患者在接受氯喹治疗后往往仍然对按蚊具有传染性。使用青蒿素联合疗法或立即开始使用伯氨喹根治治疗应降低 感染的传播性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70df/11382624/f67a39f77b75/aac.00853-24.f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70df/11382624/e105f18a4849/aac.00853-24.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70df/11382624/2387546d7306/aac.00853-24.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70df/11382624/2bced2573993/aac.00853-24.f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70df/11382624/f67a39f77b75/aac.00853-24.f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70df/11382624/e105f18a4849/aac.00853-24.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70df/11382624/2387546d7306/aac.00853-24.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70df/11382624/2bced2573993/aac.00853-24.f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70df/11382624/f67a39f77b75/aac.00853-24.f004.jpg

相似文献

1
Transmission-blocking activities of artesunate, chloroquine, and methylene blue on gametocytes.青蒿琥酯、氯喹和亚甲蓝对配子体的阻断作用。
Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0085324. doi: 10.1128/aac.00853-24. Epub 2024 Jul 26.
2
Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria.以青蒿素为基础的联合疗法治疗无并发症间日疟原虫疟疾。
Cochrane Database Syst Rev. 2013 Oct 25;2013(10):CD008492. doi: 10.1002/14651858.CD008492.pub3.
3
Primaquine for reducing Plasmodium falciparum transmission.伯氨喹用于减少恶性疟原虫传播。
Cochrane Database Syst Rev. 2012 Sep 12(9):CD008152. doi: 10.1002/14651858.CD008152.pub2.
4
Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission.伯氨喹或其他8-氨基喹啉用于减少恶性疟原虫传播。
Cochrane Database Syst Rev. 2015 Feb 19(2):CD008152. doi: 10.1002/14651858.CD008152.pub4.
5
Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission.伯氨喹或其他8-氨基喹啉用于减少恶性疟原虫传播。
Cochrane Database Syst Rev. 2014 Jun 30(6):CD008152. doi: 10.1002/14651858.CD008152.pub3.
6
Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria.以青蒿素为基础的联合疗法治疗无并发症间日疟原虫疟疾。
Cochrane Database Syst Rev. 2011 Jul 6(7):CD008492. doi: 10.1002/14651858.CD008492.pub2.
7
Azithromycin for treating uncomplicated malaria.阿奇霉素用于治疗非复杂性疟疾。
Cochrane Database Syst Rev. 2011 Feb 16;2011(2):CD006688. doi: 10.1002/14651858.CD006688.pub2.
8
Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.伯氨喹剂量与无并发症间日疟患者溶血风险:一项系统评价和个体患者数据荟萃分析
Lancet Infect Dis. 2024 Feb;24(2):184-195. doi: 10.1016/S1473-3099(23)00431-0. Epub 2023 Sep 22.
9
Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission.用于减少恶性疟原虫传播的伯氨喹或其他8-氨基喹啉类药物。
Cochrane Database Syst Rev. 2018 Feb 2;2(2):CD008152. doi: 10.1002/14651858.CD008152.pub5.
10
Therapeutic efficacy of pyronaridine-artesunate (Pyramax) in treating malaria in the central highlands of Vietnam.吡喹酮-青蒿琥酯(派姆)治疗越南北部高原疟疾的疗效。
Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0004424. doi: 10.1128/aac.00044-24. Epub 2024 Jul 24.

引用本文的文献

1
[Effect of low-dose primaquine treatment on Plasmodium vivax recurrence and transmission-blocking activity in southwest Ethiopia: a longitudinal cohort study.低剂量伯氨喹治疗对埃塞俄比亚西南部间日疟原虫复发及传播阻断活性的影响:一项纵向队列研究
Malar J. 2025 Apr 17;24(1):125. doi: 10.1186/s12936-025-05365-y.

本文引用的文献

1
Transmission-blocking activity of antimalarials for Plasmodium vivax malaria in Anopheles darlingi.按蚊中抗疟原虫药物对间日疟原虫的阻断作用。
PLoS Negl Trop Dis. 2023 Jun 16;17(6):e0011425. doi: 10.1371/journal.pntd.0011425. eCollection 2023 Jun.
2
Severe Falciparum and Vivax Malaria on the Thailand-Myanmar Border: A Review of 1503 Cases.泰国-缅甸边境地区的严重恶性疟原虫和间日疟原虫疟疾:1503 例病例回顾。
Clin Infect Dis. 2023 Sep 11;77(5):721-728. doi: 10.1093/cid/ciad262.
3
The activity of methylene blue against asexual and sexual stages of .
亚甲蓝对无性和有性阶段的 的活性。
Front Cell Infect Microbiol. 2023 Apr 18;13:1108366. doi: 10.3389/fcimb.2023.1108366. eCollection 2023.
4
Plasmodium vivax gametocytes and transmission.疟原虫配子体和传播。
Parasitol Int. 2022 Apr;87:102497. doi: 10.1016/j.parint.2021.102497. Epub 2021 Nov 6.
5
The global burden of Plasmodium vivax malaria is obscure and insidious.全球间日疟原虫疟疾负担隐晦而隐匿。
PLoS Med. 2021 Oct 7;18(10):e1003799. doi: 10.1371/journal.pmed.1003799. eCollection 2021 Oct.
6
The prevention and treatment of Plasmodium vivax malaria.疟原虫 vivax 疟疾的预防和治疗。
PLoS Med. 2021 Apr 23;18(4):e1003561. doi: 10.1371/journal.pmed.1003561. eCollection 2021 Apr.
7
Identification of the metabolites of ivermectin in humans.鉴定人体中甲氟喹的代谢物。
Pharmacol Res Perspect. 2021 Feb;9(1):e00712. doi: 10.1002/prp2.712.
8
The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study.印度尼西亚巴布亚复发性疟疾的发病和死亡风险:一项回顾性队列研究。
BMC Med. 2020 Feb 20;18(1):28. doi: 10.1186/s12916-020-1497-0.
9
Antimalarial activity of primaquine operates via a two-step biochemical relay.伯氨喹的抗疟活性通过两步生化接力来实现。
Nat Commun. 2019 Jul 19;10(1):3226. doi: 10.1038/s41467-019-11239-0.
10
Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study.绘制 2000-17 年全球间日疟原虫流行状况和临床负担图:时空建模研究。
Lancet. 2019 Jul 27;394(10195):332-343. doi: 10.1016/S0140-6736(19)31096-7. Epub 2019 Jun 19.